Skip to content
Open access

Oral microbiome–metabolome axis links glycerophospholipid dysregulation to Alzheimer’s disease

Sep 2026 · Journal of Oral Microbiology · Vol 18 · 0 citations · 71 references
Medicine

TL;DR

Tongue biofilm represents a non-invasive, cost-effective, and accessible biomarker source, offering potential for AD diagnosis and research when coupled with microbiome and metabolomic analyses.

Abstract

ABSTRACT Introduction This study aimed to evaluate the feasibility of using tongue biofilm as a non-invasive, patient-friendly, and cost-effective biomarker source for identifying early microbial and metabolic disturbances associated with Alzheimer’s disease (AD). Materials and methods A total of 62 outpatients were enrolled (31 with AD and 31 cognitively normal controls). Tongue biofilm samples were analyzed using 16S rRNA sequencing and untargeted metabolomics via UPLC-Q/TOF-MS. Additionally, cerebrospinal fluid (CSF) samples from 36 individuals (18 per group) were examined under identical untargeted metabolomics processing protocols to validate the metabolomic findings. Results and discussion Microbiome analysis revealed an increased relative abundance of Proteobacteria in the AD group, while Firmicutes and Bacteroidetes were enriched in controls. Metabolomic profiling identified 88 significantly different metabolites between groups, 64 of which achieved area under the curve (AUC) values > 0.90 in the ROC analysis. Glycerophospholipid metabolism has emerged as a key dysregulated pathway in AD, a finding further corroborated by CSF metabolomic analysis. Tongue biofilm represents a non-invasive, cost-effective, and accessible biomarker source, offering potential for AD diagnosis and research when coupled with microbiome and metabolomic analyses. Moreover, the role of glycerophospholipid metabolism in AD pathogenesis warrants further investigation.

Read PDF

Similar papers

Open access Oct 2026

Alterations in oral microbiome and salivary metabolome profiles associated with myocardial infarction: a case-control study

Abstract Background Few studies have comprehensively profiled both the salivary microbiome and metabolome in myocardial infarction (MI). This case-control study therefore characterized microbial and metabolic alterations in MI patients and identified potential diagnostic signatures. Methods Seventy participants (35 MI...

Sheng-Nan Lei, Tuo Chen, Xiao-Dong Xie et al. · 0 citations
Open access Oct 2026

Altered gut microbiota and untargeted metabolomic features in patients with schizophrenia: a case–control study

Background Mental disorders are among the leading causes of global disease burden, and their etiology spans genetic, environmental, and physiological factors. Emerging evidence suggests that the gut microbiota may contribute to the development of neuropsychiatric disorders through the microbiota–gut–brain axis. This st...

Yun-Qiang Mi, Peng Sun, Qing-Rui Hao et al. · 0 citations
Open access Oct 2026

Gut Microbiome Alterations in Alzheimer’s Disease: A Shotgun Metagenomic Case–Control Study

AD in this Central Asian cohort was associated with a less diverse, compositionally distinct gut microbiome, with depletion of butyrate-producing Firmicutes and enrichment of sulfate-reducing taxa, alongside other taxa whose direction of association differed from prior reports.

A. Issilbayeva, S. Kozhakhmetov, A. Kushugulova et al. · 0 citations
Review Open access Oct 2026

Microbiome-targeted strategies for Alzheimer’s disease: multi-omics signatures, mechanistic links, and intervention evidence

Alzheimer’s disease (AD) is increasingly studied in relation to gut microbial mechanisms because microbial metabolism, mucosal barrier function, and peripheral immune activation may influence neuroinflammation and host metabolic stress. This review evaluates microbiome-linked evidence in AD with emphasis on studies tha...

Xu-Yang Huang, Xin-Yue Zhang, Qi Zhu · 0 citations
Open access Sep 2026

Peripheral neurotransmitter metabolic signatures in schizophrenia: a targeted metabolomics study

The four-metabolite panel (α-ketoglutarate, succinic acid, tryptamine, and amino butyric acid) may provide experimental basis for further mechanistic research and therapeutic development and offer peripheral evidence supporting the core position of GABAergic dysfunction in schizophrenia.

Bing Han, Yu Guo, Baie Feng et al. · 0 citations
Open access Oct 2026

Integrated gut microbiome and fecal metabolome profiling identifies taurine-associated microbial dysbiosis across the Alzheimer’s disease clinical spectrum

Integrated multi-omic profiling reveals coordinated microbiome–metabolome dysregulation across the AD clinical spectrum, with taurine as a candidate microbial–metabolic node linking gut dysbiosis to cognitive performance.

Yi Feng, Yao Sha, Lu-Lu Xu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.